

# Norbert Vey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/969997/publications.pdf>

Version: 2024-02-01

495  
papers

18,270  
citations

14655

66  
h-index

19749

117  
g-index

516  
all docs

516  
docs citations

516  
times ranked

15907  
citing authors

#	ARTICLE	IF	CITATIONS
1	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. <i>Blood Advances</i> , 2022, 6, 1804-1812.	5.2	14
2	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. <i>Blood Cancer Journal</i> , 2022, 12, 14.	6.2	10
3	Diagnosis and treatment of therapy-related acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103607.	4.4	19
4	In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria. <i>Antibiotics</i> , 2022, 11, 291.	3.7	5
5	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1237-1252.	7.2	12
6	A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. <i>British Journal of Haematology</i> , 2022, 198, 535-544.	2.5	12
7	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. <i>Blood Advances</i> , 2022, , .	5.2	13
8	Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2022, 14, 2025.	3.7	17
9	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. <i>Leukemia</i> , 2021, 35, 893-896.	7.2	3
10	Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. <i>International Journal of Cancer</i> , 2021, 148, 375-384.	5.1	10
11	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study. <i>Leukemia Research</i> , 2021, 100, 106489.	0.8	29
12	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	7.2	5
13	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	1.4	183
14	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <i>Blood</i> , 2021, 137, 524-532.	1.4	33
15	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	5.2	56
16	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Haematologica</i> , 2021, 106, 1414-1422.	3.5	17
17	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. <i>Blood</i> , 2021, 137, 2827-2837.	1.4	36
18	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	56

#	ARTICLE	IF	CITATIONS
19	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. <i>European Journal of Haematology</i> , 2021, 106, 859-867.	2.2	2
20	Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with <i>Pneumocystis jirovecii</i> pneumonia: A propensity score analysis. <i>PLoS ONE</i> , 2021, 16, e0250611.	2.5	12
21	Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006 intermediate-risk trial. <i>European Journal of Haematology</i> , 2021, 107, 111-121.	2.2	4
22	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29
23	BTN2A1, an immune checkpoint targeting V $\beta$ 9V $\gamma$ 2 T cell cytotoxicity against malignant cells. <i>Cell Reports</i> , 2021, 36, 109359.	6.4	44
24	Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 845-852.	3.4	3
25	Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. <i>Annals of Oncology</i> , 2021, 32, 1046-1048.	1.2	15
26	958O Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial. <i>Annals of Oncology</i> , 2021, 32, S829-S830.	1.2	0
27	Herpesviridae in critically ill hematology patients: HHV-6 is associated with worse clinical outcome. <i>Journal of Critical Care</i> , 2021, 66, 138-145.	2.2	4
28	Treatment of Newly Diagnosed AML in Unfit Patients. <i>Hematologic Malignancies</i> , 2021, , 215-231.	0.2	0
29	The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute's Experience. <i>Clinical Hematology International</i> , 2021, 3, 119.	1.7	3
30	Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. <i>Cancers</i> , 2021, 13, 5608.	3.7	10
31	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 349-355.	2.4	18
32	Targeted molecular characterization shows differences between primary and secondary myelofibrosis. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 30-39.	2.8	17
33	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. <i>Cancers</i> , 2020, 12, 88.	3.7	4
34	Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e76-e81.	0.4	2
35	Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia. <i>Cancer Epidemiology</i> , 2020, 66, 101699.	1.9	8
36	Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias. <i>Haematologica</i> , 2020, 105, e340-e342.	3.5	5

#	ARTICLE	IF	CITATIONS
37	A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. <i>Blood Cancer Journal</i> , 2020, 10, 64.	6.2	18
38	Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091301.	2.5	18
39	Gains of EPOR and ERG genes in adult erythroleukaemia. <i>British Journal of Haematology</i> , 2020, 189, e174-e177.	2.5	4
40	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	2.4	53
41	Haplo Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S285.	2.0	0
42	Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome. <i>Annals of Hematology</i> , 2020, 99, 773-780.	1.8	6
43	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide: an International Collaborative Study. <i>Leukemia</i> , 2020, 34, 2333-2341.	7.2	20
44	Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation. <i>Current Oncology Reports</i> , 2020, 22, 4.	4.0	9
45	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
46	316...EVICTON Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A. , 2020, , .		4
47	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 16-18.	1.4	12
48	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. <i>Blood</i> , 2020, 136, 19-21.	1.4	5
49	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	54
50	Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study. <i>Blood</i> , 2020, 136, 15-16.	1.4	2
51	Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 23-23.	1.4	0
52	Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
53	Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
54	Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.. <i>Blood</i> , 2020, 136, 14-15.	1.4	2

#	ARTICLE	IF	CITATIONS
55	IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group. <i>Blood</i> , 2020, 136, 39-40.	1.4	1
56	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123 $\times$ CD3 Bispecific Dart $\text{\textcircled{R}}$ Molecule, in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-28.	1.4	1
57	<i>TP53</i> Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 3-4.	1.4	0
58	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. <i>Blood</i> , 2020, 136, 40-42.	1.4	7
59	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 246-249.	1.3	0
60	Clinical outcome of FLAG-IDA chemotherapy sequential with Flu $\text{\textcircled{R}}$ Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes. <i>Bone Marrow Transplantation</i> , 2019, 54, 458-464.	2.4	8
61	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019, 11, 141.	4.1	11
62	Topotecan Plus Cytarabine: An Effective and Safe Induction Regimen for Newly Diagnosed Acute Myeloid Leukemia in Patients with Cardiac Contra-Indication to Anthracyclines. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S214.	0.4	0
63	Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer. <i>Cancers</i> , 2019, 11, 1463.	3.7	13
64	Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France. <i>JAMA Network Open</i> , 2019, 2, e187147.	5.9	17
65	Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell $\text{\textcircled{R}}$ Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1803-1809.	2.0	20
66	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1730-1737.	2.4	19
67	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
68	Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1289-1293.	1.3	4
69	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1067-1076.	2.4	20
70	Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 36-42.	5.8	24
71	Flotetuzumab, an Investigational CD123 $\times$ CD3 Bispecific Dart $\text{\textcircled{R}}$ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2019, 134, 733-733.	1.4	14
72	Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study. <i>Blood</i> , 2019, 134, 1423-1423.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019, 134, 229-229.	1.4	30
74	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. <i>Blood</i> , 2019, 134, 1295-1295.	1.4	4
75	Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML. <i>Blood</i> , 2019, 134, 1416-1416.	1.4	5
76	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart <sup>®</sup> Molecule for T-Cell Redirected Therapy. <i>Blood</i> , 2019, 134, 5144-5144.	1.4	4
77	Phase 1b Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 570-570.	1.4	64
78	Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007-02 Study. <i>Blood</i> , 2019, 134, 2618-2618.	1.4	1
79	Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients. <i>Blood</i> , 2019, 134, 4625-4625.	1.4	0
80	Anti-BTN3A 20.1 Agonist Monoclonal Antibody Enhances Autologous $\hat{V}^3\hat{V}^2$ T Cells Cytotoxicity Against Primary Acute Myeloid Blasts. <i>Blood</i> , 2019, 134, 5153-5153.	1.4	4
81	Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies. <i>Blood</i> , 2019, 134, 4503-4503.	1.4	0
82	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1449-1454.	2.0	39
83	Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients. <i>Leukemia Research</i> , 2018, 68, 29-31.	0.8	5
84	Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. <i>British Journal of Haematology</i> , 2018, 181, 350-359.	2.5	11
85	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
86	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. <i>Leukemia and Lymphoma</i> , 2018, 59, 2135-2143.	1.3	5
87	Allogeneic Hematopoietic Stem Cell Transplantation for Patients Over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S58-S59.	2.0	0
88	Critically ill allogeneic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality. <i>Bone Marrow Transplantation</i> , 2018, 53, 1233-1241.	2.4	53
89	Fit $\hat{I}^1\hat{I}^2$ T-cell receptor suppresses leukemogenesis of Pten-deficient thymocytes. <i>Haematologica</i> , 2018, 103, 999-1007.	3.5	6
90	Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies. <i>British Journal of Haematology</i> , 2018, 180, 735-737.	2.5	10

#	ARTICLE	IF	CITATIONS
91	Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 330-338.	4.1	49
92	T-cell-replete haploidentical transplantation in acute myeloid leukemia. <i>Experimental Hematology</i> , 2018, 58, 5-16.	0.4	7
93	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D2;) Tj ETQq1 1 0.784314 rgBT /Overlo	1.8	110
94	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210.	1.6	32
95	Blurring lines between treatment intensity and patient fitness in elderly people with AML. <i>Lancet Haematology</i> , 2018, 5, e383-e384.	4.6	3
96	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2514-2523.	1.6	99
97	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia's Response. <i>Cancer Research</i> , 2018, 78, 6342-6343.	0.9	1
98	Association between health literacy, communication and psychological distress among myelodysplastic syndromes patients. <i>Leukemia Research</i> , 2018, 73, 44-50.	0.8	9
99	Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2063-2071.	5.2	26
100	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	5.2	114
101	Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial). <i>Haematologica</i> , 2018, 103, e519-e521.	3.5	3
102	Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e514-e518.	3.5	9
103	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. <i>Frontiers in Immunology</i> , 2018, 9, 977.	4.8	25
104	Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. <i>Haematologica</i> , 2018, 103, 2033-2039.	3.5	24
105	A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. <i>Blood</i> , 2018, 132, 467-467.	1.4	9
106	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy. <i>Blood</i> , 2018, 132, 2738-2738.	1.4	9
107	Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM. <i>Blood</i> , 2018, 132, 4368-4368.	1.4	3
108	Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 2806-2806.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasana) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. <i>Blood</i> , 2018, 132, 767-767.	1.4	21
110	Evaluation of a Standardized Geriatric Assessment at Diagnosis in a Prospective Cohort of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2671-2671.	1.4	1
111	Phase 1 Cohort Expansion of Flotetuzumab, a CD123 $\wedge$ -CD3 Bispecific Dart $\wedge$ Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 764-764.	1.4	32
112	Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results. <i>Blood</i> , 2018, 132, 5233-5233.	1.4	8
113	Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Elderly Patients with Acute Myeloid Leukemia in First Complete Remission: A Time-Dependent and Multistate Analysis from the French Innovative Leukemia Organization. <i>Blood</i> , 2018, 132, 209-209.	1.4	4
114	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide $\wedge$ an International Collaborative Study. <i>Blood</i> , 2018, 132, 80-80.	1.4	0
115	Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients. <i>Blood</i> , 2018, 132, 1401-1401.	1.4	0
116	Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bithrapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 241-242.	0.4	8
117	Impact of body $\wedge$ surface area on patients $\wedge$ outcome in younger adults with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 98, 443-449.	2.2	6
118	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 1223-1230.	1.6	37
119	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1880-1886.	1.3	14
120	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. <i>Oncolmmunology</i> , 2017, 6, e1307491.	4.6	37
121	Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. <i>Haematologica</i> , 2017, 102, 373-380.	3.5	58
122	Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. <i>Haematologica</i> , 2017, 102, e11-e14.	3.5	42
123	Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des My $\wedge$ lodysplasies</i>. <i>Haematologica</i> , 2017, 102, 728-735.	3.5	22
124	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 620-621.	2.4	23
125	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2017, 77, 6627-6640.	0.9	23
126	Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. <i>Blood Cancer Journal</i> , 2017, 7, e594-e594.	6.2	10



#	ARTICLE	IF	CITATIONS
127	Targeting apoptosis in acute myeloid leukaemia. <i>British Journal of Cancer</i> , 2017, 117, 1089-1098.	6.4	61
128	Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. <i>Blood Cancer Journal</i> , 2017, 7, e562-e562.	6.2	14
129	Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells. <i>Frontiers in Immunology</i> , 2017, 8, 64.	4.8	35
130	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2017, 8, 573.	4.8	47
131	Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS. <i>Annals of Oncology</i> , 2017, 28, v355.	1.2	4
132	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With <i>NPM1</i> Mutation: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 185-193.	1.6	227
133	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017, 35, 1591-1597.	1.6	79
134	A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7070-TPS7070.	1.6	7
135	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. <i>Oncotarget</i> , 2017, 8, 37866-37874.	1.8	10
136	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 49548-49563.	1.8	34
137	Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. <i>Oncotarget</i> , 2017, 8, 81926-81935.	1.8	15
138	Abstract 4140: Identification of a selective MKLP2/KIF20A inhibitor with high-in-vivo antitumor activity. , 2017, , .		0
139	Clinical Applications of Epigenetic Drugs. , 2016, , 329-346.		0
140	Epigenetically centered evolution in an example of myeloid malignancy. <i>American Journal of Hematology</i> , 2016, 91, E361-2.	4.1	0
141	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2016, 34, 2988-2996.	1.6	190
142	Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. <i>Haematologica</i> , 2016, 101, e427-e428.	3.5	13
143	A randomized phase II trial of azacitidine +/- epoetin- $\alpha$ in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. <i>Haematologica</i> , 2016, 101, 918-925.	3.5	55
144	The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016, 51, 1134-1136.	2.4	23

#	ARTICLE	IF	CITATIONS
145	Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2016, 172, 628-630.	2.5	16
146	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 1044-1053.	27.0	270
147	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. <i>Blood</i> , 2016, 128, 253-264.	1.4	320
148	T-Replete Haploidentical Allogeneic Transplantation Using Post-Transplantation Cyclophosphamide in Advanced Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S368-S369.	2.0	0
149	BTN3A molecules considerably improve V $\beta$ 9V $\gamma$ 2T cells-based immunotherapy in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 5, e1146843.	4.6	46
150	Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndrome. <i>Leukemia Research</i> , 2016, 46, 79-84.	0.8	1
151	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS mutant relapsed or refractory myeloid malignancies. <i>Cancer</i> , 2016, 122, 1871-1879.	4.1	113
152	Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. <i>Haematologica</i> , 2016, 101, e185-e188.	3.5	68
153	Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 307-317.	4.1	45
154	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e186-e195.	4.6	359
155	The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m <sup>2</sup> intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2315-2320.	1.3	4
156	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. <i>Cancer Research</i> , 2016, 76, 2082-2086.	0.9	24
157	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2016, 51, 194-198.	2.4	22
158	Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 119-124.	2.0	86
159	Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. <i>Leukemia</i> , 2016, 30, 966-970.	7.2	31
160	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016, 128, 1063-1063.	1.4	5
161	Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist. <i>Blood</i> , 2016, 128, 2843-2843.	1.4	4
162	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 762-762.	1.4	13

#	ARTICLE	IF	CITATIONS
163	Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial). Blood, 2016, 128, 898-898.	1.4	1
164	Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial. Blood, 2016, 128, 903-903.	1.4	6
165	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget, 2016, 7, 85937-85947.	1.8	9
166	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget, 2016, 7, 32532-32542.	1.8	75
167	Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).. Journal of Clinical Oncology, 2016, 34, 7061-7061.	1.6	0
168	Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure. Blood, 2016, 128, 348-348.	1.4	0
169	Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group. Blood, 2016, 128, 895-895.	1.4	0
170	Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation. Blood, 2016, 128, 4618-4618.	1.4	0
171	Comparison of Haploidentical T-Replete HSCT Followed with Post-Transplant High Dose Cyclophosphamide (PT-HDCy) with Matched Related (MRD) or Unrelated (UD) HSCT in Patients in or after the 6TH Decade. Biology of Blood and Marrow Transplantation, 2015, 21, S273-S274.	2.0	1
172	COMPARISON OF THREE DISTINCT PROPHYLACTIC AGENTS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015048.	1.3	6
173	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. Frontiers in Immunology, 2015, 6, 564.	4.8	24
174	French consensus on myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia: diagnosis, classification and treatment. Hematologie, 2015, 21, 46-59.	0.0	0
175	Question prompt list responds to information needs of myelodysplastic syndromes patients and caregivers. Leukemia Research, 2015, 39, 599-605.	0.8	17
176	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5, e292-e292.	6.2	21
177	PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia. Leukemia, 2015, 29, 1202-1206.	7.2	8
178	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Leukemia Research, 2015, 39, 296-306.	0.8	50
179	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	10.7	129
180	Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome “Emphasis on optimized dosing schedules and new formulations. Leukemia Research, 2015, 39, 1028-1033.	0.8	19

#	ARTICLE	IF	CITATIONS
181	213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES. <i>Leukemia Research</i> , 2015, 39, S107.	0.8	0
182	Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. <i>Cancer</i> , 2015, 121, 1809-1816.	4.1	31
183	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. <i>American Journal of Hematology</i> , 2015, 90, 859-863.	4.1	17
184	Comparison of 60 or 90 mg/m <sup>2</sup> of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. <i>American Journal of Hematology</i> , 2015, 90, E29-30.	4.1	19
185	Azacitidine for the treatment of relapsed and refractory AML in older patients. <i>Leukemia Research</i> , 2015, 39, 124-130.	0.8	63
186	Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients. <i>American Journal of Hematology</i> , 2015, 90, E22-4.	4.1	16
187	Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup. <i>Leukemia and Lymphoma</i> , 2015, 56, 847-857.	1.3	28
188	Abstract CT113: A phase III, multicenter, randomized study evaluating the efficacy and safety and efficacy of erythrocyte encapsulated l-asparaginase (Ery001) versus native l-asparaginase (L-asp) in combination with COOPRALL regimen in patients with first relapse of acut. <i>Cancer Research</i> , 2015, 75, CT113-CT113.	0.9	1
189	Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study. <i>Blood</i> , 2015, 126, 1-1.	1.4	29
190	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. <i>Blood</i> , 2015, 126, 2872-2872.	1.4	1
191	Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs). <i>Blood</i> , 2015, 126, 2880-2880.	1.4	1
192	Updated Clinical Activity of Graspa Versus Native l-Asparaginase in Combination with Cooprrall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). <i>Blood</i> , 2015, 126, 3723-3723.	1.4	5
193	Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). <i>Blood</i> , 2015, 126, 3734-3734.	1.4	1
194	Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial. <i>Blood</i> , 2015, 126, 3736-3736.	1.4	1
195	The Role of Donor CMV Serostatus on Outcome after T-Cell Replete Haplo-SCT and Post-Transplant Cyclophosphamide: A Cohort Analysis on 207 Consecutive Adult Patients. <i>Blood</i> , 2015, 126, 4401-4401.	1.4	2
196	Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group. <i>Blood</i> , 2015, 126, 451-451.	1.4	3
197	Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy. <i>Blood</i> , 2015, 126, 95-95.	1.4	3
198	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3065-3065.	1.6	21

#	ARTICLE	IF	CITATIONS
199	Drug monitoring of ERY001 (erythrocyte encapsulated L-asparaginase) and native L-asparaginase (L-ASP) in combination with COOPRALL regimen in Phase 3 randomized trial in patients with relapsed acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18036-e18036.	1.6	1
200	Role of <i>ASXL1</i> and <i>TP53</i> mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. <i>Oncotarget</i> , 2015, 6, 8388-8396.	1.8	69
201	French consensus on myelodysplastic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. <i>Hematologie</i> , 2015, 21, 28-45.	0.0	1
202	Allogeneic HSCT for Patients Aged More Than 55 Years with Myeloid Malignancies: Results of 171 Patients. <i>Blood</i> , 2015, 126, 5525-5525.	1.4	0
203	Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study. <i>Blood</i> , 2015, 126, 1665-1665.	1.4	1
204	Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA). <i>Blood</i> , 2015, 126, 2893-2893.	1.4	0
205	Single Center Experience of Allogenic Hematopoietic Stem Cell Transplantation in 100 Patients with Myelodysplasia: The Impact of Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 5537-5537.	1.4	0
206	A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study. <i>Blood</i> , 2015, 126, 2900-2900.	1.4	1
207	Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells. <i>Blood</i> , 2015, 126, 2580-2580.	1.4	0
208	Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia. <i>Leukemia</i> , 2014, 28, 440-443.	7.2	21
209	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. <i>Haematologica</i> , 2014, 99, 46-53.	3.5	44
210	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2014, 5, 122.	4.8	75
211	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. <i>Leukemia and Lymphoma</i> , 2014, 55, 2114-2119.	1.3	11
212	Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2211-2212.	1.3	7
213	566 GNS396 and analogues are potent new small molecules to target and kill chemotherapy-resistant subpopulation cells in acute myeloid leukemia. <i>European Journal of Cancer</i> , 2014, 50, 183.	2.8	0
214	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. <i>Haematologica</i> , 2014, 99, 1762-1768.	3.5	35
215	Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. <i>Clinical Microbiology and Infection</i> , 2014, 20, 160-166.	6.0	52
216	5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. <i>European Journal of Cancer</i> , 2014, 50, 196.	2.8	12

#	ARTICLE	IF	CITATIONS
217	Preferences of Older Adults with Cancer for Involvement in Decision-Making about Research Participation. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1191-1193.	2.6	4
218	Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. <i>Leukemia</i> , 2014, 28, 2422-2424.	7.2	52
219	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 1380-1386.	3.5	31
220	Contributing to research via biobanks: what it means to cancer patients. <i>Health Expectations</i> , 2014, 17, 523-533.	2.6	8
221	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 29-33.	0.8	16
222	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 604-609.	4.1	36
223	Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. <i>American Journal of Hematology</i> , 2014, 89, 410-416.	4.1	91
224	De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. <i>Intensive Care Medicine</i> , 2014, 40, 41-49.	8.2	106
225	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. <i>American Journal of Hematology</i> , 2014, 89, 83-87.	4.1	25
226	Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors. <i>Bone Marrow Transplantation</i> , 2014, 49, 1246-1247.	2.4	1
227	Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related or Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1560-1565.	2.0	11
228	Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 370-374.	2.0	40
229	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 1849-1853.	1.3	6
230	International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1919-1926.	1.6	166
231	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e185-e187.	3.5	27
232	Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. <i>Haematologica</i> , 2014, 99, 37-45.	3.5	38
233	Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). <i>Blood</i> , 2014, 124, 116-116.	1.4	55
234	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. <i>Blood</i> , 2014, 124, 117-117.	1.4	27

#	ARTICLE	IF	CITATIONS
235	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). <i>Blood</i> , 2014, 124, 409-409.	1.4	11
236	Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study. <i>Blood</i> , 2014, 124, 4288-4288.	1.4	1
237	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	1.4	7
238	Impact of High Body Surface Area on AML Outcome in Younger Patients: A Goelams Study. <i>Blood</i> , 2014, 124, 973-973.	1.4	4
239	Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Oncotarget</i> , 2014, 5, 3168-3172.	1.8	58
240	H3K27me3 Level of the HIST1 Cluster Defines an Epigenetic Marker of Acute Myeloid Leukemia with Prognostic Value. <i>Blood</i> , 2014, 124, 2326-2326.	1.4	0
241	The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio. <i>Blood</i> , 2014, 124, 323-323.	1.4	0
242	Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. <i>Cancer</i> , 2013, 119, 986-992.	4.1	62
243	P-273 Azacitidine treatment for patients with myelodysplastic syndrom and acute myeloid leukemia harboring chromosome 3q abnormalities. <i>Leukemia Research</i> , 2013, 37, S145-S146.	0.8	0
244	A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. <i>Leukemia</i> , 2013, 27, 1479-1486.	7.2	50
245	Impact of Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation on Women's Fertility. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 704-710.	0.4	24
246	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). <i>Leukemia Research</i> , 2013, 37, 637-640.	0.8	45
247	Donor CD3+ lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: Single-center experience. <i>Experimental Hematology</i> , 2013, 41, 17-27.	0.4	10
248	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2213-2223.	1.4	313
249	Nelarabine for T Cell Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: An Opportunity to Improve Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1124-1126.	2.0	21
250	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2428-2436.	1.6	462
251	An Identical Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic (ALLO) Hematopoietic Stem Cell Transplantation (HSCT) in 222 Patients with Hematologic Malignancies: A Monocenter Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S282.	2.0	0
252	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. <i>Leukemia</i> , 2013, 27, 1401-1403.	7.2	102

#	ARTICLE	IF	CITATIONS
253	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1228-1234.	1.3	43
254	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>European Journal of Haematology</i> , 2013, 90, 355-364.	2.2	66
255	5-azacitidine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 419-428.	1.6	1
256	Targeting Age-Related Changes in the Biology of Acute Myeloid Leukemia: Is the Patient Seeing the Progress?. <i>Interdisciplinary Topics in Gerontology</i> , 2013, 38, 73-84.	3.6	13
257	Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1472-1477.	2.4	17
258	Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. <i>American Journal of Hematology</i> , 2013, 88, 556-559.	4.1	30
259	Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. <i>Leukemia and Lymphoma</i> , 2013, 54, 1538-1540.	1.3	12
260	Concomitant germline <i>RUNX1</i> and acquired <i>ASXL1</i> mutations in a T-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2013, 91, 277-279.	2.2	25
261	Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. <i>Leukemia</i> , 2013, 27, 1283-1290.	7.2	65
262	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. <i>Haematologica</i> , 2013, 98, 576-583.	3.5	9
263	A phase I first-in-human study with tefinostat â€” a monocyte/macrophage targeted histone deacetylase inhibitor â€” in patients with advanced haematological malignancies. <i>British Journal of Haematology</i> , 2013, 162, 191-201.	2.5	32
264	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. <i>Blood</i> , 2013, 122, 3169-3177.	1.4	169
265	Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. <i>Haematologica</i> , 2013, 98, e18-e19.	3.5	29
266	Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities. <i>Blood</i> , 2013, 122, 1512-1512.	1.4	1
267	Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. <i>Blood</i> , 2013, 122, 2681-2681.	1.4	1
268	Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2696-2696.	1.4	7
269	Comparison Of Umbilical Cord Blood and Haploidentical Donor Grafts In Adults With High Risk Hematologic Diseases After Fludarabine Cyclophosphamide and TBI 2 Cy Based Reduced-Intensity Conditioning Regimen Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3288-3288.	1.4	6
270	Micafungin Versus Fluconazole Or Itraconazole For Prophylaxis Against Invasive Fungal Infections During Neutropenia In Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 4564-4564.	1.4	1



#	ARTICLE	IF	CITATIONS
271	Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine. <i>Blood</i> , 2013, 122, 498-498.	1.4	17
272	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 620-620.	1.4	2
273	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. <i>Blood</i> , 2013, 122, 658-658.	1.4	1
274	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€“ Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. <i>Blood</i> , 2013, 122, 495-495.	1.4	0
275	A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q â€“ A Study By The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 2750-2750.	1.4	2
276	Use Of Unrelated Donors In Elderly Patients (age >60 years) Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation For Hematologic Malignancies. <i>Blood</i> , 2013, 122, 5544-5544.	1.4	0
277	Reduced Intensity Conditioning Based On Fludarabine, Intravenous Busulfan (2 Days) and Antithymocyte Globulins (2 Days) Results In High Disease Free Survival Without Persisting Gvhd In Patients Transplanted For Hematological Malignancies: Large Single Center Cohort With Long Follow-Up. <i>Blood</i> , 2013, 122, 3364-3364.	1.4	0
278	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2012, 23, 2687-2695.	1.2	23
279	Adherence to Leukemia Maintenance Therapy: A Comparative Study Among Children, Adolescents, and Adults. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 428-439.	0.8	29
280	The increase from 2.5 to 5â€“mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 639-645.	2.4	73
281	Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. <i>Bone Marrow Transplantation</i> , 2012, 47, 549-555.	2.4	42
282	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1641-1646.	1.6	49
283	Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. <i>Leukemia and Lymphoma</i> , 2012, 53, 2186-2191.	1.3	7
284	Immunotherapy of acute myeloid leukemia based on Î³ T cells. <i>Oncolmmunology</i> , 2012, 1, 1614-1616.	4.6	11
285	Phase I and pharmacokinetic study of elacytarabine, a novel 5â€“-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. <i>Leukemia</i> , 2012, 26, 1686-1689.	7.2	18
286	Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. <i>Haematologica</i> , 2012, 97, 213-218.	3.5	37
287	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. <i>Blood</i> , 2012, 120, 4317-4323.	1.4	247
288	The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. <i>Blood</i> , 2012, 120, 5084-5085.	1.4	50

#	ARTICLE	IF	CITATIONS
289	Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 158, 581-588.	2.5	26
290	Subsequent Hematopoietic Stem Cell Transplantation (HSCT) Associated with Longer Survival in Patients with Relapsed/Refractory (R/R) Acute Myelogenous Leukemia (AML) After Clo+ Ara-C or Ara-C Alone: A Landmark Analysis from the Classic I Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S211-S212.	2.0	0
291	Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: A GOELAMS study. <i>American Journal of Hematology</i> , 2012, 87, 1052-1056.	4.1	20
292	PICALM-MLLT10 acute myeloid leukemia: A French cohort of 18 patients. <i>Leukemia Research</i> , 2012, 36, 1365-1369.	0.8	36
293	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. <i>Leukemia</i> , 2012, 26, 662-674.	7.2	72
294	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. <i>Blood</i> , 2012, 119, 3211-3218.	1.4	220
295	Human V $\beta$ 9V $\alpha$ 2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts. <i>Journal of Immunology</i> , 2012, 188, 4701-4708.	0.8	112
296	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 743-755.	2.8	139
297	Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. <i>American Journal of Hematology</i> , 2012, 87, 659-662.	4.1	67
298	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2492-2499.	1.6	165
299	Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. <i>British Journal of Haematology</i> , 2012, 156, 619-625.	2.5	32
300	Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?. <i>Leukemia Research</i> , 2012, 36, 397-400.	0.8	17
301	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. <i>British Journal of Haematology</i> , 2012, 157, 764-766.	2.5	49
302	Bortezomib combined with low-dose cytarabine in Intermediate and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. <i>British Journal of Haematology</i> , 2012, 158, 232-237.	2.5	13
303	Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. <i>Annals of Hematology</i> , 2012, 91, 39-46.	1.8	12
304	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). <i>Blood</i> , 2012, 120, 3561-3561.	1.4	10
305	Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. <i>Blood</i> , 2012, 120, 422-422.	1.4	3
306	Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts). <i>Blood</i> , 2012, 120, 890-890.	1.4	1

#	ARTICLE	IF	CITATIONS
307	Design of N-substituted Amino Caproic Hydroxamic Acid Histone Deacetylase Inhibitors Reveal an Essential Role for Cap Atomic Composition. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 801-806.	1.7	0
308	Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn) Tj ETQq0 0,0 rgBT /Oyerlock 10	1.4	4
309	LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.. <i>Blood</i> , 2012, 120, 3031-3031.	1.4	0
310	The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.. <i>Blood</i> , 2012, 120, 3029-3029.	1.4	0
311	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 1697-1697.	1.4	0
312	Post-Transplant Outcome in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Who Received Conditioning Regimen Based On Fludarabin, Busulfan and Anti-Thymoglobulin Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 2013-2013.	1.4	0
313	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. <i>Blood</i> , 2012, 120, 46-46.	1.4	1
314	Risk Factors of GANCICLOVIR-RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients. <i>Blood</i> , 2012, 120, 4186-4186.	1.4	0
315	Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2012, 120, 4505-4505.	1.4	4
316	Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 287-295.	4.1	35
317	Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. <i>Blood</i> , 2011, 118, 5099-5107.	1.4	50
318	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. <i>Blood</i> , 2011, 117, 403-411.	1.4	348
319	Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. <i>Blood</i> , 2011, 118, 679-685.	1.4	68
320	Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 6650-6659.	1.4	72
321	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. <i>Blood</i> , 2011, 118, 3824-3831.	1.4	187
322	Asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005 randomized trial. <i>British Journal of Haematology</i> , 2011, 153, 58-65.	2.5	118
323	A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogenous leukaemia patients: a GOELAMS study. <i>Leukemia</i> , 2011, 25, 939-944.	7.2	101
324	Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. <i>Leukemia</i> , 2011, 25, 1207-1209.	7.2	35

#	ARTICLE	IF	CITATIONS
325	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. <i>Leukemia</i> , 2011, 25, 1147-1152.	7.2	430
326	Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletionâ€”The GFM experience. <i>Leukemia Research</i> , 2011, 35, 1444-1448.	0.8	36
327	Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. <i>Leukemia Research</i> , 2011, 35, 1530-1533.	0.8	16
328	Improved outcome of patients with lowâ€”and intermediateâ€”risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine. <i>Cancer</i> , 2011, 117, 974-981.	4.1	19
329	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. <i>Leukemia Research</i> , 2011, 35, 863-867.	0.8	44
330	Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2011, 1, e33-e33.	6.2	36
331	Consent for Biobanking: Assessing the Understanding and Views of Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2011, 103, 154-157.	6.3	29
332	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. <i>Journal of Clinical Oncology</i> , 2011, 29, 3322-3327.	1.6	421
333	Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2011, 1, e18-e18.	6.2	17
334	Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 1000-1005.	2.4	35
335	Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 2189-2189.	1.4	4
336	Clofarabine Combinations in Adults with Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): A GRAALL Report. <i>Blood</i> , 2011, 118, 2586-2586.	1.4	4
337	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). <i>Blood</i> , 2011, 118, 609-609.	1.4	8
338	Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study. <i>Blood</i> , 2011, 118, 79-79.	1.4	77
339	Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. <i>Blood</i> , 2011, 118, 972-972.	1.4	1
340	Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS201-TPS201.	1.6	2
341	A randomized phase III study of elacytarabine versus limited investigatorâ€™s choice in patients with refractory acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS206-TPS206.	1.6	1
342	A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS207-TPS207.	1.6	1

#	ARTICLE	IF	CITATIONS
343	RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age. <i>Blood</i> , 2011, 118, 945-945.	1.4	0
344	Combination of Cytarabine and Topotecan Improves Response Rate for Patients Treated for Acute Myeloid Leukemia with Persistent Disease After Frontline Induction. <i>Blood</i> , 2011, 118, 2605-2605.	1.4	0
345	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. <i>Blood</i> , 2011, 118, 1533-1533.	1.4	0
346	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. <i>Blood</i> , 2011, 118, 410-410.	1.4	0
347	Fertility in Female Patients After Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning (RIC allo-SCT). <i>Blood</i> , 2011, 118, 3057-3057.	1.4	0
348	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. <i>Blood</i> , 2010, 115, 1690-1696.	1.4	232
349	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. <i>BMC Cancer</i> , 2010, 10, 401.	2.6	140
350	Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2010, 38, 55-60.	0.4	16
351	Reduced-intensity conditioning with Fludarabine, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. <i>Experimental Hematology</i> , 2010, 38, 1241-1250.	0.4	36
352	Alteration of cohesin genes in myeloid diseases. <i>American Journal of Hematology</i> , 2010, 85, 717-719.	4.1	46
353	A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 254-257.	0.8	35
354	Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients. <i>Leukemia Research</i> , 2010, 34, 1430-1436.	0.8	60
355	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 151, 365-375.	2.5	199
356	Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. <i>Leukemia</i> , 2010, 24, 467-469.	7.2	29
357	Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. <i>Leukemia</i> , 2010, 24, 1539-1541.	7.2	7
358	Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 815-821.	1.6	70
359	Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2010, 45, 1574-1575.	2.4	2
360	Laromustine (cloretazine). <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 657-667.	1.8	4

#	ARTICLE	IF	CITATIONS
361	IV Busulfan-Based Reduced Intensity Regimen (RIC) Before Allogeneic Stem Cell Transplantation Is Well Tolerate And Effective In Patients With Hematological Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S295.	2.0	0
362	The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. <i>Blood</i> , 2010, 116, 2315-2323.	1.4	79
363	A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia. <i>Current Medical Research and Opinion</i> , 2010, 26, 2653-2660.	1.9	1
364	Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL) Tj ETQq0 0 0 rgBT /Overlock 10	1.4	10
365	Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?. <i>Blood</i> , 2010, 116, 1868-1868.	1.4	1
366	Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/â~ Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone. <i>Blood</i> , 2010, 116, 1880-1880.	1.4	6
367	Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS. <i>Blood</i> , 2010, 116, 439-439.	1.4	10
368	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2010, 116, 508-508.	1.4	7
369	Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2010, 116, 976-976.	1.4	2
370	Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs). <i>Blood</i> , 2010, 116, 442-442.	1.4	1
371	Treatment of Advanced CMML by Azacitidine (AZA) In a Compassionate Program. the GFM Experience In 38 Patients (pts). <i>Blood</i> , 2010, 116, 4023-4023.	1.4	1
372	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. <i>Blood</i> , 2010, 116, 2171-2171.	1.4	0
373	AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM). <i>Blood</i> , 2010, 116, 2911-2911.	1.4	0
374	Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs). <i>Blood</i> , 2010, 116, 4002-4002.	1.4	0
375	A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age. <i>Blood</i> , 2010, 116, 2125-2125.	1.4	0
376	Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin. <i>Blood</i> , 2010, 116, 1320-1320.	1.4	0
377	Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2010, 116, 2916-2916.	1.4	0
378	A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study. <i>Blood</i> , 2010, 116, 4003-4003.	1.4	2

#	ARTICLE	IF	CITATIONS
379	A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial. <i>Blood</i> , 2010, 116, 3996-3996.	1.4	0
380	Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 4188-4188.	1.4	0
381	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009, 94, 1676-1681.	3.5	234
382	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. <i>Journal of Clinical Oncology</i> , 2009, 27, 4747-4753.	1.6	123
383	Mutations of polycomb-associated gene <i>ASXL1</i> in myelodysplastic syndromes and chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 145, 788-800.	2.5	537
384	Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a "donor" versus "no donor" comparison. <i>Leukemia</i> , 2009, 23, 194-196.	7.2	51
385	Natural killer and $\gamma\delta$ T cells in haematological malignancies: enhancing the immune effectors. <i>Trends in Molecular Medicine</i> , 2009, 15, 275-284.	6.7	45
386	Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL. <i>Leukemia and Lymphoma</i> , 2009, 50, 485-487.	1.3	9
387	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. <i>Blood</i> , 2009, 113, 3947-3952.	1.4	158
388	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009, 114, 3285-3291.	1.4	264
389	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with larmustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. <i>Blood</i> , 2009, 114, 4027-4033.	1.4	52
390	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.. <i>Blood</i> , 2009, 114, 1049-1049.	1.4	4
391	Azacitidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 1054-1054.	1.4	5
392	Azacitidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 843-843.	1.4	13
393	A Phase II Study of Post-Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.. <i>Blood</i> , 2009, 114, 844-844.	1.4	29
394	Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 2764-2764.	1.4	20
395	Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: Report of a new case and review of the literature. <i>Leukemia Research</i> , 2008, 32, 1304-1308.	0.8	24
396	Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA group. <i>Leukemia Research</i> , 2008, 32, 1741-1750.	0.8	50

#	ARTICLE	IF	CITATIONS
397	Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. <i>Bone Marrow Transplantation</i> , 2008, 42, 689-691.	2.4	8
398	Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. <i>BMC Cancer</i> , 2008, 8, 299.	2.6	109
399	Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 135-141.	2.5	67
400	Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor. <i>Critical Care</i> , 2008, 12, R17.	5.8	24
401	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i> , 2008, 111, 574-582.	1.4	295
402	Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1806-1813.	3.5	131
403	Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL. <i>Blood</i> , 2008, 112, 139-139.	1.4	2
404	Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group. <i>Blood</i> , 2008, 112, 761-761.	1.4	0
405	GRASPALL 2005.01 Clinical Study: L-Asparaginase Loaded into Red Blood Cells Is Effective at Depleting Serum Asparagine in Children and Adults with Relapsed Acute Lymphoblastic Leukaemia (ALL). <i>Blood</i> , 2008, 112, 306-306.	1.4	3
406	Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 26, 25-31.	1.6	75
407	Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. <i>Haematologica</i> , 2007, 92, 1327-1334.	3.5	33
408	Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2007, 92, 533-541.	3.5	74
409	Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. <i>Cancer</i> , 2007, 109, 1376-1383.	4.1	150
410	Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. <i>Cancer</i> , 2007, 110, 2747-2755.	4.1	22
411	High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 301-306.	2.4	49
412	Gentuzumab-Ozogamicin (GO) Plus Idarubicin (I) and Cytarabine (C) as Induction Treatment for Elderly Patients with Poor-Risk Cytogenetics Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 1839-1839.	1.4	2
413	Maintenance Therapy by Clivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 2812-2812.	1.4	3
414	Decision Criteria for the Futility of Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 2861-2861.	1.4	2



#	ARTICLE	IF	CITATIONS
415	Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia (ALL) at Diagnosis and/or at First Relapse: Results from the GET-LALA Group.. Blood, 2007, 110, 4326-4326.	1.4	1
416	High Relapse Rate of Acute Myeloid Leukemia with Translocation (8;21) or Inversion (16) in Elderly Patients Treated with Conventional Chemotherapy.. Blood, 2007, 110, 4365-4365.	1.4	2
417	Impact of CRi on the Outcome of Elderly Patients with Acute Myeloid Leukemia.. Blood, 2007, 110, 4384-4384.	1.4	1
418	Phase II Study of VNP40101M (Clotetazine®) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).. Blood, 2007, 110, 917-917.	1.4	4
419	A Phase I Study with CP-4055 In Patients with Hematologic Malignancies.. Blood, 2007, 110, 901-901.	1.4	0
420	Outcome of Patients with T-Cell Lymphoblastic Leukemia or Lymphoma: The GRAALL Experience.. Blood, 2007, 110, 2818-2818.	1.4	0
421	Graft-Versus Host Disease (GVHD) and Infectious Complications Following Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults.. Blood, 2007, 110, 4985-4985.	1.4	0
422	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a "Donor" Versus "No Donor" Comparison.. Blood, 2007, 110, 1090-1090.	1.4	0
423	Anti-Acute Myeloid Leukemia Activity of Chaetocin, a Novel Epigenetic Drug Inhibitor Inducing Oxidative Stress.. Blood, 2007, 110, 889-889.	1.4	1
424	Results of the AFR07 Prospective Study in De Novo Philadelphia Positive ALL Patients Aged over 55 Years: Efficacy and Safety of a Glivec® Based Induction Followed by Maintenance Therapy with Glivec® and Pegasys®.. Blood, 2007, 110, 2816-2816.	1.4	0
425	The Dose of CD34+ Cells Negatively Impacts the Outcome of Patients Treated with Genoidentical Allo SCT Prepared with a Reduced Intensity Conditioning (RIC).. Blood, 2007, 110, 1086-1086.	1.4	1
426	Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. British Journal of Haematology, 2006, 135, 408-410.	2.5	8
427	Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplantation, 2006, 37, 709-710.	2.4	23
428	Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia, 2006, 20, 336-344.	7.2	42
429	A phase II study of clotetazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research, 2006, 30, 1591-1595.	0.8	24
430	Clotetazine for the treatment of acute myeloid leukemia. Expert Review of Anticancer Therapy, 2006, 6, 321-328.	2.4	8
431	Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study. Journal of Clinical Oncology, 2006, 24, 2465-2471.	1.6	95
432	Towards a Pediatric Approach in Adults with Acute Lymphoblastic Leukemia (ALL): The GRAALL-2003 Study.. Blood, 2006, 108, 147-147.	1.4	12

#	ARTICLE	IF	CITATIONS
433	Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.. Blood, 2006, 108, 2664-2664.	1.4	4
434	Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience.. Blood, 2006, 108, 2678-2678.	1.4	3
435	Assessment of Peripheral Blood (PB) Blast Decrease Rate by Multiparameter Flow Cytometry: A New Prognostic Factor in Acute Myeloblastic Leukaemia (AML). A Goelams Study.. Blood, 2006, 108, 1892-1892.	1.4	0
436	Impact of Comorbidities on the Outcome of Elderly Patients with Acute Myeloid Leukemia.. Blood, 2006, 108, 1976-1976.	1.4	0
437	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Salvage Treatment for Relapsing Multiple Myeloma (MM): A "Donor" vs. "No Donor" Comparison.. Blood, 2006, 108, 3003-3003.	1.4	0
438	Outcome of Treatment after First Relapse in Adults Patients with Acute Lymphoblastic Leukemia (ALL) Initially Treated by the LALA-94 Trial.. Blood, 2006, 108, 1876-1876.	1.4	2
439	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Refractory or Relapsed Non-Hodgkin's Lymphoma (NHL).. Blood, 2006, 108, 5356-5356.	1.4	0
440	Sustained Effect of First Line Sequential Therapy with Intensive Consolidation Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) after Reduced Intensity Conditioning (RIC) for Patients with Acute Myeloblastic Leukemia (AML) in First Complete Remission (CR1).. Blood, 2006, 108, 3000-3000.	1.4	0
441	A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 1970-1970.	1.4	0
442	Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).. Blood, 2006, 108, 2850-2850.	1.4	7
443	Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood, 2005, 105, 3072-3078.	1.4	63
444	Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 2005, 106, 4407-4411.	1.4	76
445	One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. British Journal of Haematology, 2005, 129, 403-410.	2.5	12
446	Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 901-906.	2.4	15
447	The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia, 2005, 19, 916-920.	7.2	101
448	Acute leukemia during pregnancy. Cancer, 2005, 104, 110-117.	4.1	136
449	Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer, 2005, 104, 1931-1938.	4.1	56
450	Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience. Journal of Clinical Oncology, 2005, 23, 7676-7684.	1.6	59

#	ARTICLE	IF	CITATIONS
451	Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. International Journal of Oncology, 2005, 26, 1485.	3.3	8
452	Early allogeneic stem cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat analysis of the long-term experience of the BGMT group. Biology of Blood and Marrow Transplantation, 2005, 11, 17-18.	2.0	5
453	Arsenic trioxide for the treatment of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy, 2004, 5, 613-621.	1.8	11
454	Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial. Journal of Clinical Oncology, 2004, 22, 4075-4086.	1.6	480
455	Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution. Bone Marrow Transplantation, 2004, 33, 177-182.	2.4	12
456	Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 527-530.	2.4	34
457	Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene, 2004, 23, 9381-9391.	5.9	44
458	CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2004, 32, 1097-1102.	0.4	36
459	Sometimes appendicitis can wait. American Journal of Hematology, 2004, 76, 312-313.	4.1	5
460	The benefit of induction chemotherapy in patients age ≥ 75 years. Cancer, 2004, 101, 325-331.	4.1	60
461	Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood, 2004, 103, 4666-4668.	1.4	58
462	Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).. Blood, 2004, 104, 747-747.	1.4	5
463	A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.. Blood, 2004, 104, 5194-5194.	1.4	0
464	Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.. Blood, 2004, 104, 619-619.	1.4	11
465	The Role of Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML): A Donor vs. No Donor Comparison.. Blood, 2004, 104, 2325-2325.	1.4	0
466	Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. Experimental Hematology, 2003, 31, 873-880.	0.4	20
467	Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL. Bone Marrow Transplantation, 2003, 32, 961-963.	2.4	7
468	Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia, 2003, 17, 811-813.	7.2	22

#	ARTICLE	IF	CITATIONS
469	Myelodysplastic features developing in Philadelphia-negative cells during imatinib mesylate therapy for CML: report of a new case. <i>Leukemia</i> , 2003, 17, 1901-1902.	7.2	11
470	Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. <i>Leukemia</i> , 2003, 17, 2168-2177.	7.2	111
471	Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. <i>Blood</i> , 2003, 102, 462-469.	1.4	175
472	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. <i>Blood</i> , 2003, 102, 470-476.	1.4	182
473	Re: Familial Multiple Myeloma: a Family Study and Review of the Literature. <i>Journal of the National Cancer Institute</i> , 2002, 94, 461-462.	6.3	12
474	Transient detection of $\beta$ -galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy. <i>Experimental Hematology</i> , 2002, 30, 108-115.	0.4	5
475	Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+ /CD38- primitive haematopoietic progenitors. <i>British Journal of Haematology</i> , 2002, 119, 115-118.	2.5	44
476	Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. <i>Leukemia</i> , 2002, 16, 2129-2133.	7.2	66
477	Simultaneous Occurrence of Kaposi's Sarcoma and Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 41, 425-428.	1.3	22
478	Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report. <i>Bone Marrow Transplantation</i> , 2001, 28, 1157-1160.	2.4	16
479	Survey of Early Disappearance of BCR/ABL Fusion Transcript after Allogeneic or Autologous Stem Cell Transplantation for Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 42, 945-952.	1.3	4
480	Lymphomatoid papulosis associated with both severe hypereosinophilic syndrome and CD30 positive large T-cell lymphoma. <i>Cancer</i> , 2000, 89, 2138-2143.	4.1	25
481	High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 251-255.	2.4	108
482	Rescue of haemopoiesis by a combination of growth factors including stem-cell factor. <i>Lancet</i> , The, 2000, 356, 1325-1326.	13.7	22
483	CD34+ immunoselected cells for poor graft function following allogeneic BMT. <i>Cytotherapy</i> , 2000, 2, 367-370.	0.7	14
484	Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 1999, 17, 2819-2819.	1.6	132
485	Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy. <i>Blood</i> , 1999, 93, 3149-3150.	1.4	18
486	Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study. <i>Investigational New Drugs</i> , 1999, 17, 89-95.	2.6	31

#	ARTICLE	IF	CITATIONS
487	Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involment. <i>Hematology and Cell Therapy</i> , 1999, 41, 5-11.	0.7	2
488	Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients. <i>Journal of Immunotherapy</i> , 1999, 22, 175-181.	2.4	9
489	Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage Therapy. <i>Blood</i> , 1999, 93, 3149-3150.	1.4	1
490	Second Neoplasms Following High-dose Chemotherapy and Autologous Stem Cell Transplantation for Malignant Lymphomas: A Report of Six Cases in a Cohort of 171 Patients from a Single Institution. <i>Leukemia and Lymphoma</i> , 1998, 31, 187-194.	1.3	29
491	A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1998, 31, 343-349.	1.3	49
492	Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1722-1729.	1.6	56
493	A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 21, 107-114.	1.3	15
494	Autologous Transplantation of Blood Stern Cells Mobilized with Filgrastim Alone in 93 Patients with Malignancies: The Number of CD34+ Cells Reinfused Is the Only Factor Predicting Both Granulocyte and Platelet Recovery. <i>Stem Cells and Development</i> , 1996, 5, 663-670.	1.0	46
495	Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration. <i>British Journal of Haematology</i> , 1996, 93, 42-44.	2.5	25